Amgen fourth-quarter profit tops Street view, but 2017 outlook light

(Reuters) - Amgen Inc on Thursday posted a higher-than-expected fourth-quarter profit, helped by a jump in sales of its Enbrel rheumatoid arthritis drug, but it issued a 2017 sales and earnings forecast range below current Wall Street estimates.

Amgen fourth-quarter profit tops Street view, but 2017 outlook light
Read More


Bagikan Berita Ini